Surveillance Instead of Surgery: — Your BRCA Screening Schedule

No. A BRCA variant is a risk factor, not a certainty. Many carriers who follow a regular surveillance programme never develop cancer. Others may develop cancer that is caught early, when treatment is most effective. The result tells your medical team that closer monitoring is needed — it does not predict what will happen to you specifically. Your genetic counsellor can help you understand where your personal risk sits within the published range.

For breast cancer, the combination of annual MRI and mammogram detects most cancers early. For ovarian cancer, the evidence base is different: surveillance has not been shown to reduce ovarian cancer deaths the way breast surveillance has. That is why many oncologists have a separate conversation about risk-reducing surgery for the ovaries, usually after a woman has completed her family — typically between age 35 and 45 depending on your variant. This decision is not urgent and should be made with time, information, and specialist input, not in the weeks immediately after receiving your result.

Men who carry a BRCA2 variant have a lifetime breast cancer risk of around six percent, according to NCCN estimates — substantially above the general male population figure of around 0.1 percent. BRCA1 and BRCA2 also raise the risk of prostate cancer and pancreatic cancer in men. Male carriers are advised to perform monthly breast self-examination, attend regular clinical breast examinations, and discuss prostate cancer screening from around age 40 with their oncologist. Screening recommendations for men are less established than for women, and a genetic counsellor should guide the plan.

First-degree relatives — parents, siblings, and children — each have a 50 percent chance of carrying the same variant. Genetic testing for adults is generally recommended from age 18, or earlier in specific circumstances your genetic counsellor will explain. Your counsellor can also help you think through how to approach these conversations with family members, which are often emotionally complicated. Knowing early gives relatives the option to begin surveillance or make informed decisions before any symptoms appear, and that knowledge is protective.

There is currently no clinical evidence that any Ayurvedic or herbal preparation reduces BRCA-related cancer risk. That does not mean you cannot practise traditional medicine for general wellbeing — many people do. What matters from a cancer monitoring perspective is that you tell your treating team everything you are taking, because some supplements can interact with medications or affect test results. Do not delay or replace surveillance appointments on the advice of a traditional practitioner, however well-intentioned.

Missing an appointment in a high-risk surveillance programme matters more than missing an ordinary health check. Contact your oncologist or the clinic nurse navigator as soon as you can to reschedule — do not wait until your next routine visit. If you cannot access imaging at your usual centre, your team can help arrange it elsewhere. At CION, surveillance is coordinated across more than 35 centres, so a gap at one location does not have to mean a gap in your monitoring. If cost or distance is making surveillance difficult to maintain, raise this directly with your team — there may be options you are not aware of.